Efficacy of Fetal Stem Cells use in Complex Treatment of Patients with Insulin-resistant Type 2 Diabetes Mellitus

Dr. Mariya Demchuk*, Dr. Olena Ivankova, Dr. Mariya Klunnyk, Dr. Iryna Matiyashchuk, Dr. Nataliya Sych, Dr. Andriy Sinelnik, Dr. Alla Novytska and Khrystyna Sorochynska

Cell Therapy Center EmCell, Kyiv City, Ukraine

Abstract

Objective: To identify efficacy of fetal stem cells in treatment of the patients suffering from Type 2 diabetes mellitus in presence of insulin resistance and to summarize all characteristics of post-transplantation disease course.

Materials and Methods: 42 patients suffering from Type 2 diabetes mellitus (T2DM) in presence of insulin resistance were examined including 27 men and 15 women. G semi-in was controlled by diet therapy in 7 patients (16.7%), whereas the rest of the patients were recommended antihyperglycemic medicines (biguanides, thiazolidinediones, sulfonylurea derivatives and a-reductase inhibitors). Fetal stem cells (FSCs) were administered in complex therapy for the patients with T2DM and the data of clinical, laboratory and anthropometric investigations were analyzed over the study period.

Results: Positive effects to values of carbohydrate and lipid metabolism, as well as arterial blood pressure (ABP) in T2DM have been justified. FSCs capacity to decreasing insulin resistance (in accordance with the HOMA-IR scale) which results in stable continuous diabetes mellitus compensation was established.

Conclusion: FSCs use in complex treatment of patients with T2DM stabilizes disease compensation and leads to decrease in hyperinsulinemia and lower insulin resistance.

Keywords: Fetal stem cells; Insulin resistance; Treatment of type 2 diabetes mellitus

Abbreviations: T2DM: Type 2 Diabetes Mellitus; FSCs: Fetal Stem Cells; IR: Insulin Resistance; HOMA: Homeostasis Model Assessment; HbA1c: Glycated Hemoglobin; LDL-C: Low Density Lipoprotein in Cholesterol Level; VLDL-C: Very Low Density Lipoprotein Cholesterol Level; HDL-C: High Density Lipoprotein Cholesterol Level; TG: Triglycerides; PFI: Plasma Fasting Insulin; PFG: Plasma Fasting Glucose; IHD: Ischemic Heart Disease; ABP: Arterial Blood Pressure; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; BMI: Body Mass Index; WC: Waist Circumference; DMSO: Dimethyl Sulfoxide; CLIA: Chemiluminescent Immunoassay; ECLIA: Immunochemical Method With ECL Detection; IDF: International Diabetes Federation

Introduction

Diabetes mellitus (DM) is a markedly spread endocrine illness worldwide, which has already grown into a non-infectious epidemic. In accordance with the data of World Health Organization (WHO) and International Diabetic Federation (IDF) in 2015 diabetes prevalence reached 415 million persons all over the world [1,2], and with relation to disease incidence rates, the number of patients can amount as many as 592 million persons until 2035 [3]. T2DM specific gravity comprises from 85 to 90% among all cases of this disease. As far as often DM disease cannot be diagnosed over the years due to lack of hyperglycemia symptoms – subsequently, the patients would often suffer 1-2 disease complications prior to T2DM diagnosis could be confirmed in the patient [4]. In the first instance, early invalidity and high mortality rates among T2DM patients are induced by development of vascular complications. Approximately 80% of the patients with T2DM are suffering from arterial hypertension – their life span is threefold lower compared to this disease prevalence among the healthy population. Spread of ischemic heart disease (IHD) along with associated T2DM illness is 2-4 times more frequent among the patients; the risk of acute myocardial infarction increases 6-10 times and acute disturbances of cerebral circulation – are 4-7-fold more often in comparison with the same problems in the patients without DM [5,6].

Disruption of insulin secretion by β-cells of pancreatic islets of Langerhans and low resistance to insulin in peripheral tissues – insulin resistance (IR) have been outlined as the principal mechanisms for T2DM development. In particular, IR is considered to be a pathophysiology background for T2DM as the main mechanism which defines appearance of associated disturbances in metabolism of carbohydrates and lipids as well as disorders of arterial blood pressure (ABP) and endothelial dysfunctions [7,8]. The above mentioned disorders tend to cause fast arteriosclerosis development and high mortality rates which are superimposed by cardiovascular diseases among the patients suffering from T2DM [9].

The basic metabolic changes of IR are associated with decrease of insulin physiological function at the cellular level. Hyperglycemia emerges resulting from decreased reuptake of glucose in peripheral tissues and enhanced gluconeogenesis along with elevation of glucose produced by the liver. Hyperlipidemia is the result of decreased fatty acids synthesis and lipolysis stimulation with accumulation of free fatty acids (FFA) in blood plasma, which are likely to become a source of building-up atherogenic very low-density lipoproteins (VLDL).

*Corresponding author: Dr. Mariya Demchuk, Internal Medicine, Cell Therapy Center EmCell, Kyiv City, Ukraine, Tel: 380672331982; +38 067 236 27 61 E-mail: infocenter@emcell.com

Received April 17, 2016; Accepted June 20, 2016; Published July 27, 2016


Copyright: © 2016 Demchuk MP, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
triglycerides (TG) inside of hepatocytes and is a consequence of decreased atherogenic elimination of VLDL lipoproteins – and low-density lipoproteins (LDL). Besides, dyslipidemia develops because of decreased high-density lipoproteins cholesterol levels (HDL-C) since those require apoproteins and phospholipids which are released from VLDL and LDL during lipolysis. FFA supplied to systemic blood circulation disrupt all functions of insulin receptors and intensify IR (lipotoxicity effect).

IR induces compensatory hyperproduction of insulin by β-cells of pancreatic islets of Langerhans and results in persistent and stable hyperinsulinemia. It has been experimentally proved that insulin exerts its immediate atherogenic effects on the walls of vessels by stimulating proliferation and migration of nonstriated myocytes, growth of fibroblasts, activation of blood coagulation system, and decreased performance of fibrinolysis. Thus, high blood insulin levels contribute to appearance and progression of arteriosclerosis in the patients with DM.

Hyperinsulinemia tends to be a marker of IR and is commonly detected at onset of T2DM disease. With the lapse of time, when IR rate increases – capacity for insulin production by the β-cells of pancreatic islets of Langerhans is exhausted. Primarily, function of fast secretion of postprandial insulin is affected (phase 1 of insulin secretion) whereas 2 phase (phase of basal insulin secretion) remains surplus. High blood glucose level enhances IR in peripheral tissues and diminishes insulin secretory function by β-cells – and, in fact, reveals its glucose toxicity. On average over 10–15 years after diagnosis-making, the patients may experience stable hyperinsulinemia which requires prescription of replacement therapy and insulin administration [10,11].

In view of established by the world diabetes science mechanisms of T2DM genesis there have been changes in regard to treatment of DM patients. The main aim is to decrease the risks of vascular complications and promote a likelihood of longer life expectancy among the patients. In conformity with recommendations from American Diabetes Association (ADA) concerning T2DM (2011), it is reasonable to prescribe antihyperglycemic medicines in tablets only if diet therapy fails, notably, non-judicious medicines use must be avoided – this can stimulate hyperinsulinemia. In case of necessary selection of peroral antihyperglycemic preparation to achieve disease compensation, doctors prefer medicines which not only induce hypoglycemic effects, but also do not lead to marked hyperinsulinemia and medicines volume was recorded among all patients undergoing treatment within the last 3 years. Stable morning hyperglycemia has been recently used with confidence in diabetes science as a method of therapy for DM patients [14]. Among various advantages of FSCs treatment hypoglycemic effects have been mainly defined. In 2002 experimental study by Shiroi A., Yoshikawa M. (Japan) identified that at the stages of embryogenesis FSCs of mice synthesize insulin and medicines volume was recorded among all patients undergoing treatment within the last 3 years. Stable morning hyperglycemia has been recently used with confidence in diabetes science as a method of therapy for DM patients [14]. Among various advantages of FSCs treatment hypoglycemic effects have been mainly defined. In 2002 experimental study by Shiroi A., Yoshikawa M. (Japan) identified that at the stages of embryogenesis FSCs of mice synthesize insulin and substances with insulin-mimetic action exerting their proximate antihypoglycemic effect. Besides, these cells can differentiate into β-cells of pancreatic islets of Langerhans which induce not polipotent, but rather pluripotent effects [15]. Since 1991 the treatment methods for different types of DM using FSCs have been established by us; both indications and contraindications for FSCs use have been developed [14-17], and eventually treatment proved its high effectiveness for type 1 DM (T1DM) [18-22] and T2DM on different stages of the disease [23,24]. Effective FSCs application for metabolic syndrome has been recently recorded [25].

Materials and Methods

Patients

A group of patients suffering from T2DM was under study after administration of FSCs. Diabetes disease was defined according to the 1999 WHO diagnostic criteria [26]. The study was conducted in accordance with good clinical practice, Helsinki declaration as well as the ethical standards for work with human embryonic tissues approved by the Ministry of Health of Ukraine [27]; methodology recommendations at the Ministry of Health of Ukraine, Academy of Medical Science of Ukraine, Ukrainian Center for Scientific Medical Information and Patent Licensing on treatment of patients with diabetes mellitus [28]. All the patients gave their informed consent prior to treatment. Study group included 42 patients with T2DM: 27 men and 15 women whose mean age made up 56.7 ± 6.3 years (Table 1).

Clinical observation and examination of the patients was performed during 1 year. In the clinical group disease duration after diagnosis making and right before FSCs transplantation constituted from 6 months up to 3.5 years (2.7 ± 0.5 yrs. on average). Elevation of body weight was recorded among the patients. Body mass index (BMI) ranged from 29.3 to 36.7 kg/m², the mean value made up 34.49 ± 2.81 kg/m². Before FSCs use 8 patients (19%) were administered diet therapy only, the rest of patients received antihyperglycemic agents per os (biguanides, thiazolidinediones, sulfonylurea derivatives, and α-reductase inhibitors). No modification in treatment regimen and medicines volume was recorded among all patients undergoing treatment within the last 3 years. Stable morning hyperglycemia has been observed in all patients (from 7.8 to 10.1 mmol/L; 8.73 ± 0.64 mmol/L on average) within the range of postprandial blood glucose from 8.1 to 14.9 mmol/L, 11.23 ± 1.96 mmol/L on average. The level of HbA1c composed 8.31 ± 1.60% on average. The changes in blood lipid profile with increased cholesterol level over 34.6% on average;

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Patients with T2DM</th>
<th>Healthy individuals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients, sex (m/w)</td>
<td>42 (27/15)</td>
<td>19</td>
</tr>
<tr>
<td>Age, years</td>
<td>56.7 ± 6.3</td>
<td>53.4 ± 3.7</td>
</tr>
<tr>
<td>Duration of presented signs</td>
<td>2.7 ± 0.5</td>
<td>-</td>
</tr>
<tr>
<td>WC, cm (m/w)</td>
<td>113.24 ± 10.65/101.24 ± 9.73</td>
<td>90.24 ± 4.37/77.62 ± 4.25</td>
</tr>
<tr>
<td>Body mass index (BMI), kg/m²</td>
<td>34.49 ± 2.81</td>
<td>23.67 ± 2.42</td>
</tr>
<tr>
<td>Fasting glycemic index (Gi), mmol/L</td>
<td>8.73 ± 0.64</td>
<td>4.71 ± 1.08</td>
</tr>
<tr>
<td>Fasting insulinemia score, mmol/L</td>
<td>27.81 ± 6.2</td>
<td>10.37 ± 1.35</td>
</tr>
<tr>
<td>C-peptide levels, ng/mL</td>
<td>6.84 ± 1.87</td>
<td>1.98 ± 0.48</td>
</tr>
<tr>
<td>HbA1c, %</td>
<td>8.31 ± 1.60</td>
<td>4.92 ± 1.23</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>8.13 ± 1.28</td>
<td>2.14 ± 0.31</td>
</tr>
<tr>
<td>Cholesterol, mmol/L</td>
<td>7.01 ± 0.36</td>
<td>4.76 ± 0.23</td>
</tr>
<tr>
<td>Triglycerides (TG), mmol/L</td>
<td>2.01 ± 0.45</td>
<td>1.04 ± 0.09</td>
</tr>
<tr>
<td>HDL, mmol/L (m/w)</td>
<td>0.72 ± 0.14/0.90 ± 0.08</td>
<td>1.37 ± 0.34/1.42 ± 0.16</td>
</tr>
<tr>
<td>LDL, mmol/L</td>
<td>5.23 ± 0.74</td>
<td>2.36 ± 0.67</td>
</tr>
<tr>
<td>VLDL, mmol/L</td>
<td>1.14 ± 0.19</td>
<td>0.63 ± 0.28</td>
</tr>
</tbody>
</table>

Table 1: Clinical and laboratory characteristics of the patients.
an elevation of LDL-C and VLDL-C concentration over mean 34% and 28% were recorded respectively, and the range of HDL-C in the patients decreased by 25%. Blood serum C-peptide level increased from 4.83 to 8.36 ng/mL and on average these ranges made up 6.84 ± 1.87 ng/mL. All patients reported mean fasting hyperinsulinemia of 27.81 ± 6.2 mcU/mL and laboratory evidences of insulin resistance: HOMA-IR value ranged from 4.95 to 9.34 (8.13 ± 1.28 on average). Disease clinical manifestations were not significant in regard to functional disorders and psychophysiology reactions in 10 patients (23.8%); 32 patients (76.2%) were presented with 1-II stage hypertension, 9 patients (21.4%) - IHD, 6 patients (14.3%) - suffered from diseases of peripheral arteries. In accordance with the indications and following the recommendations of IDF (2012) [29], the patients underwent the following drugs therapy: angiotensin converting enzyme inhibitors or angiotensin receptor blockers, diuretics, calcium channel blockers, \( \beta \)-blockers, antiaggregants, and statins.

The parameters of carbohydrate metabolism. Plasma fasting glucose (FFG) levels and postprandial glucose were measured using the method of hexokinase enzyme system (reference range, 3.88-6.38 mmol/L); glycated hemoglobin (HbA1c) – by use of immunoturbidimetric technique (reference range, 4.8-5.9%); plasma fasting insulin (PFI) levels were controlled by immunochemical method with ECL detection (ECLIA), (reference range, 2.6-24.9 mcU/mL) – Cobas 6000 automated analyzer using the testing systems of Roche Diagnostics (Switzerland). C-peptide blood serum level was determined by indirect double stage chemiluminescent immunoassay (CLIA) (reference range, 0.8-4.2 ng/mL) – Liaison automated analyzer by application of Diasorin test systems (Italy). The value of insulin resistance was identified by use of HOMA (Homeostasis Model Assessment) method according to the following formula: HOMA-IR = fasting plasma insulin (mcU/mL) \times\text{ fasting plasma glucose (mmol/L)}/22.5 [30], (reference range<3).

The parameters of lipid metabolism. Serum total cholesterol (TC), TG, HDL-C, LDL cholesterol (LDL-C) levels were measured by use of enzymatic methods adapted to Cobas 6000 analyzer with application of the testing systems of Roche Diagnostics (Switzerland). VLDL cholesterol (VLDL-C) level was calculated according to the Friedewald formula [31].

**STEM CELL PROCEDURE**

A single application of cryopreserved fetal stem cell suspensions was conducted for the patients. The FSCs were received from the tissues of human cadaveric embryos with 5-8 weeks of gestation as a result of legal abortion due to family planning reasons and social indications. Collection of abortive material was performed in accordance with the recommendations of IDF (2012) [29], the patients underwent the following drugs therapy: angiotensin converting enzyme inhibitors or angiotensin receptor blockers, diuretics, calcium channel blockers, \( \beta \)-blockers, antiaggregants, and statins.

The parameters of carbohydrate metabolism. Plasma fasting glucose (FFG) levels and postprandial glucose were measured using the method of hexokinase enzyme system (reference range, 3.88-6.38 mmol/L); glycated hemoglobin (HbA1c) – by use of immunoturbidimetric technique (reference range, 4.8-5.9%); plasma fasting insulin (PFI) levels were controlled by immunochemical method with ECL detection (ECLIA), (reference range, 2.6-24.9 mcU/mL) – Cobas 6000 automated analyzer using the testing systems of Roche Diagnostics (Switzerland). C-peptide blood serum level was determined by indirect double stage chemiluminescent immunoassay (CLIA) (reference range, 0.8-4.2 ng/mL) – Liaison automated analyzer by application of Diasorin test systems (Italy). The value of insulin resistance was identified by use of HOMA (Homeostasis Model Assessment) method according to the following formula: HOMA-IR = fasting plasma insulin (mcU/mL) \times\text{ fasting plasma glucose (mmol/L)}/22.5 [30], (reference range<3).

The parameters of lipid metabolism. Serum total cholesterol (TC), TG, HDL-C, LDL cholesterol (LDL-C) levels were measured by use of enzymatic methods adapted to Cobas 6000 analyzer with application of the testing systems of Roche Diagnostics (Switzerland). VLDL cholesterol (VLDL-C) level was calculated according to the Friedewald formula [31].

Cryopreservation was made by means of 5% dimethyl sulfoxide (DMSO) cryoprotectant following a three-stage program for freezing at the rate of 1°C/min and crystal forming initiation in the controlled-rate freezer chamber (Ice Cube 14S, SY-LAB Gerate GmbH). Suspensions containing stem cells were placed into liquid nitrogen at −196°C for storage in a well-equipped cryobank. Water bath thawing of cryopreserved suspension at 37.5°C was performed immediately before cells administration. Fetal stem cell viability was tested by trypan blue staining and cells were counted using 2 methods in parallel: Goryaev chamber and Automated Cell Counter NC-100 (Nucleo Counter Type 900-004 Chemo Metec, Denmark 2010). Cells viability before freezing made up 83.0 ± 3.0%; after cryopreservation and water bath thawing – the same rate accounted not less than 74.8 ± 1.03%. CD34+ levels were calculated by application of flow cytometry (Becton Dickinson, Franklin Lakes, NJ, USA) with fluorescent tagged antibodies (Santa Cruz Biotechnology, Dallas, TX, USA).

The mode of administration – drip intravenous infusion, in volume from 0.5 to 3.0 mL, with cells concentration from 1.0 to 100x10^6 mL, and values of CD34+ progenitor cells made up from 1 up to 20 x 10^7/mL.

**Statistics**

The results were statistically processed by use of software Statistics v.6.0 (StatSoft Inc., Tulsa, USA) with assessment of the mean values and standard deviation. Significant difference between the scores was calculated by application of the Students t-test. \( p<0.05 \) was considered as statistically significant deviation.

**Results and Discussion**

All patients successfully tolerated FSCs treatment and no complications were reported. 36 patients (85.7%) observed manifestations of syndrome of early post-transplantation improvements: decreased weakness, increased physical and mental capacity, better concentration, stabilization in sleep patterns, improved mood and decrease of depression events. Treatment results were more marked during the first 2-4 weeks; later effects insignificantly diminished and were preserved over 2-4 months. Over the first week after FSCs use 18 patients (42.9%) reported increased blood glucose levels by 15-25%. Hyperglycemia tended to decrease even without supplementary antihyperglycemic therapy. Later the parameters of glycaemia gradually dropped down among the patients (Figure 1) which demanded subsequent taper of medicines. No evidence of severe hypoglycemic response was reported by the patients.

Tendency to decreased fasting blood glucose levels was demonstrable over 2-3 months of observation (8.09 ± 0.65 mmol/L on average, \( p<0.05 \)). Likelihood of decreased fasting glycaemia levels was also revealed over 5-7 months after treatment and on average made up 6.73 ± 0.42 mmol/L (\( p<0.05 \)); still remaining preserved for the total period under observation. The level of postprandial hyperglycaemia was likely decreased over 5-7 months of the study. 27 patients (64.3%) reported 1.5-2-fold lowering in doses of hypoglycemic medicines over 4-6 months after FSCs administration. Gradual decrease in HbA1c levels happened simultaneously to improved values of blood glucose (Figure 2).

The similar decrease was observed over 2-3 months (7.73 ± 0.62% on average, \( p<0.05 \), with stabilization of this score in 32 patients (76.2%) over 5-7 months of the study (6.46 ± 0.67% on average, \( p>0.05 \)) and within the next months of observation (on average 6.13 ± 0.82%, \( p<0.05 \)). It is worth to sum up that FSCs capacity to influence blood

**Statistics**

The results were statistically processed by use of software Statistics v.6.0 (StatSoft Inc., Tulsa, USA) with assessment of the mean values and standard deviation. Significant difference between the scores was calculated by application of the Students t-test. \( p<0.05 \) was considered as statistically significant deviation.

**Results and Discussion**

All patients successfully tolerated FSCs treatment and no complications were reported. 36 patients (85.7%) observed manifestations of syndrome of early post-transplantation improvements: decreased weakness, increased physical and mental capacity, better concentration, stabilization in sleep patterns, improved mood and decrease of depression events. Treatment results were more marked during the first 2-4 weeks; later effects insignificantly diminished and were preserved over 2-4 months. Over the first week after FSCs use 18 patients (42.9%) reported increased blood glucose levels by 15-25%. Hyperglycemia tended to decrease even without supplementary antihyperglycemic therapy. Later the parameters of glycaemia gradually dropped down among the patients (Figure 1) which demanded subsequent taper of medicines. No evidence of severe hypoglycemic response was reported by the patients.

Tendency to decreased fasting blood glucose levels was demonstrable over 2-3 months of observation (8.09 ± 0.65 mmol/L on average, \( p<0.05 \)). Likelihood of decreased fasting glycaemia levels was also revealed over 5-7 months after treatment and on average made up 6.73 ± 0.42 mmol/L (\( p<0.05 \)); still remaining preserved for the total period under observation. The level of postprandial hyperglycaemia was likely decreased over 5-7 months of the study. 27 patients (64.3%) reported 1.5-2-fold lowering in doses of hypoglycemic medicines over 4-6 months after FSCs administration. Gradual decrease in HbA1c levels happened simultaneously to improved values of blood glucose (Figure 2).

The similar decrease was observed over 2-3 months (7.73 ± 0.62% on average, \( p<0.05 \), with stabilization of this score in 32 patients (76.2%) over 5-7 months of the study (6.46 ± 0.67% on average, \( p>0.05 \)) and within the next months of observation (on average 6.13 ± 0.82%, \( p<0.05 \)). It is worth to sum up that FSCs capacity to influence blood
glucose parameters in DM patients is clinically significant since 1% decrease of glycated hemoglobin value has been proved to result in 21% lower diabetes mortality rates, acute myocardial infarction risks decreased over 14%, microvascular complications – over 37%, and 47% lower mortality resulting from diseases of peripheral arteries were reported [32,33].

During analysis of insulin susceptibility among 39 patients in the group under study (92.9%) decrease in parameter of HOMA-IR was demonstrable: over 2-3 months after FSCs transplantation by 1.5-1.7-fold (4.91 ± 0.38 on average, p<0.05), and as much as 2.4-2.6-fold over 5-7 months (3.1 ± 0.96 on average, p<0.05) and was the same until the end of the year under observation (Figure 3).

Decreased parameter of blood serum C-peptide in patients was shown over 2-3 months under observation (on average by 4.92 ± 0.53, p<0.05) the same value was stable in 32 patients (76.2%) over 5-7 months (3.22 ± 0.41 on average, p<0.05) and over 10-12 months (2.92 ± 0.35 on average, p<0.05) (Figure 4).

During assessment of lipids metabolism values, the next positive changes were also reported: within 10-12 months after FSCs transplantation 34 patients (81%) demonstrated low levels of cholesterol, TG, LDL and VLDL cholesterol – by 20-24%, and elevation of HDL cholesterol by 21-25% was characteristic (Figure 5).

Waist circumference (WC) and excessive body weight have been known as absolute risk factors of cardiovascular diseases development [34]. Favorable changes were observed in 36 patients within the study group (85.7%) in respect to lowering of body weight, BMI and WC over 12 months after FSCs treatment (Table 2).

FSCs induce a favorable effect on ABP in patients with T2DM. The parameters of systolic (SBP) and diastolic (DBP) arterial blood pressure were gradually decreased over 2-3 months after treatment by FSCs in 83.4% of patients. Steady stabilization of ABP levels which reached the target ranges was observed over 10-12 months after cells administration (Table 2). Volume of antihypertensive medicines therapy (quantity of medical drugs and their dosage) were not changed or their 1.5-2-fold dose tapering was attested compared to the same before treatment using FSCs.

A number of clinical studies have been recently performed in world diabetes science which conclusively shown and proved the provisions on the principal factors contributing to T2DM progression and appearance of severe disease complications [1,4,9,12,13]. Precise targets...
of therapy to be achieved in treatment of each patient with T2DM were established accordingly. The levels of glycated hemoglobin, fasting and postprandial blood glucose, lipid profile, arterial blood pressure and body weight are among these principal targets of DM therapy. Owing to presence of pleiotropic action after FSCs administration (persistent improvement of carbohydrates values, lipids metabolism, and...
hemodynamic rates etc.) recorded during this study, administration of FSCs in complex treatment of patients with T2DM is justified as clinically effective and reliable method of treatment.

Conclusion

Use of fetal stem cells in combined treatment of the patients with T2DM is a safe and effective method which contributes to compensation of carbohydrates and lipids metabolism in the patients. The following significant clinical effects of FSCs have been observed:

1. Syndrome of early post-transplantation improvements. Favorable changes in overall physical and emotional states were reported in 85.7% of the patients.

2. Hypoglycemic effect. Gradual decrease of fasting blood glucose, postprandial glycaemia and HbA1c has been observed in all patients over 2-3 months after FSCs treatment with significant lowering over 5-7 months and preserved effects of treatment up to 12 months. Volume of antihyperglycemic therapy remained unchanged in 35.7% of patients compared with people without diabetes in a large U.K. primary care database. Diabetes Care 36: 2366-2371. [PubMed]


Table 2: Hemodynamic and anthropometric parameters in patients with T2DM before and after FSCs treatment.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Before FSCT</th>
<th>over 3 months</th>
<th>over 12 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP, mm. Hg</td>
<td>164.3 ± 12.3</td>
<td>135.4 ± 10.7</td>
<td>124.3 ± 12.2*</td>
</tr>
<tr>
<td>DBP, mm. Hg</td>
<td>92.1 ± 9.6</td>
<td>87.9 ± 9.1</td>
<td>78.1 ± 9.8</td>
</tr>
<tr>
<td>WC, cm</td>
<td>113.24 ± 10.6101.24</td>
<td>111.61 ± 12.34</td>
<td>106.38 ± 12.74*</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>34.49 ± 2.81</td>
<td>32.61 ± 1.63</td>
<td>31.64 ± 1.57</td>
</tr>
</tbody>
</table>

Note: * - p<0.05 — in comparison with the level before FSCs transplantation.


